TD Asset Management
RPRX icon

TD Asset Management’s Royalty Pharma RPRX Stock Holding History

TD Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.8M Buy
567,497
+202,004
+55% +$10.5M 0.03% 406
2026
Q1 		$17.5M Buy
365,493
+127,596
+54% +$5.59M 0.01% 537
2025
Q4 		$9.19M Buy
237,897
+43,695
+22% +$1.67M 0.01% 679
2025
Q3 		$6.85M Buy
194,202
+91,136
+88% +$3.3M 0.01% 730
2025
Q2 		$3.71M Buy
103,066
+19,855
+24% +$658K ﹤0.01% 806
2025
Q1 		$2.59M Buy
83,211
+27,718
+50% +$879K ﹤0.01% 906
2024
Q4 		$1.42M Buy
55,493
+10,499
+23% +$278K ﹤0.01% 1071
2024
Q3 		$1.27M Buy
44,994
+822
+2% +$22.8K ﹤0.01% 1148
2024
Q2 		$1.16M Sell
44,172
-24,880
-36% -$690K ﹤0.01% 1133
2024
Q1 		$2.1M Sell
69,052
-151,131
-69% -$4.46M ﹤0.01% 1008
2023
Q4 		$6.18M Sell
220,183
-70,300
-24% -$1.93M 0.01% 710
2023
Q3 		$7.88M Buy
290,483
+96,026
+49% +$2.85M 0.01% 630
2023
Q2 		$5.98M Sell
194,457
-7,856
-4% -$266K 0.01% 703
2023
Q1 		$7.29M Buy
202,313
+996
+0.5% +$36.9K 0.01% 668
2022
Q4 		$7.96M Buy
201,317
+9,888
+5% +$413K 0.01% 645
2022
Q3 		$7.72M Sell
191,429
-14,348
-7% -$613K 0.01% 653
2022
Q2 		$8.65M Buy
205,777
+37,742
+22% +$1.55M 0.01% 642
2022
Q1 		$6.55M Buy
168,035
+628
+0.4% +$24.7K 0.01% 760
2021
Q4 		$6.67M Buy
167,407
+12,915
+8% +$502K 0.01% 793
2021
Q3 		$5.58M Sell
154,492
-1,000
-0.6% -$38.9K 0.01% 792
2021
Q2 		$5.94M Buy
155,492
+2,500
+2% +$106K 0.01% 788
2021
Q1 		$6.67M Buy
152,992
+5,800
+4% +$275K 0.01% 753
2020
Q4 		$7.37M Sell
147,192
-111,699
-43% -$4.74M 0.01% 684
2020
Q3 		$10.9M Buy
258,891
+70,000
+37% +$3M 0.02% 521
2020
Q2 		$9.17M Buy
+188,891
New +$9.35M 0.01% 530

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TD Asset Management's RPRX Position: Q2 2026 in Review

TD Asset Management increased its Royalty Pharma (RPRX) stake by 55% in Q2 2026, buying an estimated $10.5M and bringing the position to 567,497 shares worth $31.8M. The position accounts for 0.03% of the portfolio, ranked #406.

TD Asset Management first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 515 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • TD Asset Management held 567,497 shares of Royalty Pharma worth $31.8M as of Q2 2026.
  • TD Asset Management bought 202,004 Royalty Pharma shares in Q2 2026, an estimated $10.5M.
  • Royalty Pharma made up 0.03% of TD Asset Management's portfolio in Q2 2026, its #406 holding.
  • TD Asset Management first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 515 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.